Amgen Inc.

NASDAQ:AMGN

Drug Manufacturers - General

Healthcare
$443.89 -2.03%

-$6.93 today

Market cap
$240.11B
Beta
0.42
P/E (TTM)
23.2
EPS (TTM)
$14.44
Dividend yield
2.93%
52W Low $267.83High $391.29

Volume 2.58M

Average 2.76M

AMGN Common Stock Issued

Cash raised by issuing new shares.

Amgen Inc.NASDAQ: AMGN

Common Stock Issued · Q2 FY2026 · quarter ended Jun 2026

Common stock issued outflow grows to $0

Q2 FY2026 common stock issued was $0, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $0.

Context

  • Common stock issued amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Common stock issued increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock issued holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Common Stock Issued vs competitors

How AMGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Common stock issued amounts to 0.0% of revenue for AMGN, versus a peer median of 0.1%.
AMGN Competitors
Common Stock Issued for AMGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$3.86B USD+179.6%—3.9%
AZNAstraZeneca PLCLTM Sep 2026$568.66M USD+26.6%—0.9%
MRKMerck & Co., Inc.LTM Jun 2026$261M USD+987.5%-37.9%0.4%
ABBVAbbVie Inc.LTM Jun 2026$111M USD+1010.0%—0.2%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$29M USD-73.9%—0.1%
NVSNovartis AGLTM Jun 2026$18.02M USD——0.0%
GSKGSK plcLTM Jun 2026£10.39M GBP-20.1%-21.9%0.0%
AMGNAmgen Inc.LTM Jun 2026$0 USD——0.0%
LLYEli Lilly and CompanyLTM Jun 2026$0 USD——0.0%
PFEPfizer Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding AMGN) —+103.1%-29.9%0.1%

Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income5.89B6.55B6.72B4.09B7.71B
Depreciation & Amortization3.4B3.42B4.07B5.59B5.17B
Deferred Income Tax(453M)(1.2B)(1.27B)(1.23B)(721M)
Stock-Based Compensation341M401M431M530M494M
Change in Working Capital(1.19B)(733M)(484M)2.37B(1.98B)
Accounts Receivables(429M)(746M)(1.02B)441M(2.68B)
Inventory(165M)(742M)491M2.53B886M
Accounts Payables(69M)154M(402M)312M428M
Other Working Capital(531M)601M442M(920M)(616M)
Other Non-Cash Items1.28B1.28B(991M)141M(715M)
Operating Cash Flow9.26B9.72B8.47B11.49B9.96B
Capital Expenditures(880M)(936M)(1.11B)(1.1B)(1.86B)
Acquisitions (Net)(2.69B)(3.73B)(26.99B)0(53M)
Purchases of Investments(8.9B)(2.59B)(1M)00
Sales of Investments13.23B1.22B1.67B00
Other Investing Activities(35M)(12M)225M50M(32M)
Investing Cash Flow733M(6.04B)(26.2B)(1.05B)(1.94B)
Debt Repayment795M6.62B25.68B(4.26B)(5.68B)
Common Stock Issued00000
Common Stock Repurchased(4.98B)(6.36B)0(200M)0
Dividends Paid(4.01B)(4.2B)(4.56B)(4.83B)(5.12B)
Other Financing Activities(78M)(103M)(72M)(124M)(52M)
Financing Cash Flow(8.27B)(4.04B)21.05B(9.42B)(10.86B)
Effect of Forex Changes00000
Net Change in Cash1.72B(360M)3.32B1.03B(2.84B)
Free Cash Flow8.38B8.79B7.36B10.39B8.1B

Amgen Inc.

NASDAQ:AMGN

Intrinsic Alpha fair value

Locked

Current Price

$443.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.